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We analyzed the long-term outcomes of pediatric patients registered in the European Group for Blood
and Marrow Transplantation database who underwent hematopoietic stem cell transplantation (HSCT) for
severe treatment refractory autoimmune cytopenia. With a median follow-up of 100 months, event-free
survival was 54% overall, with no signiﬁcant difference between allogeneic HSCT (n ¼ 15) and autologous
HSCT (n ¼ 7) recipients (58% versus 42%; P ¼ .50). Despite a trend toward failure of response or relapse after
autologous HSCT compared with allogeneic HSCT, the difference was not signiﬁcant (43% versus 13%; P ¼ .30).
Treatment-related mortality was high in both HSCT groups (29% and 16%; P ¼ .09). Based on the limited
numbers of subjects in this retrospective analysis, both allogeneic and autologous HSCT may induce complete
and persistent responses in approximately one-half of pediatric patients with severe refractory autoimmune
cytopenia, although treatment-related toxicity is high.
 2013 American Society for Blood and Marrow Transplantation.edgments on page 668.
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12.12.008INTRODUCTION
Autoimmune cytopenias are virtually all responsive to
low-dose immunosuppressive therapy and other simple
treatment measures, such as splenectomy. However, in
rare cases, they are highly resistant or have a heavy
dependency on long-term therapy with corticosteroids
and other immunosuppressants, resulting in a persistent life-
threatening state [1-12]. In this context, hematopoietic stem
cell transplantation (HSCT) has been reported as a treatment
for immune thrombocytopenia (ITP), autoimmune hemolytic
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Figure 1. EFS after allogeneic HSCT and autologous HSCT (58.8 versus 42.8%;
P ¼ .50).
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cytopenias. Many uncertainties remain, however, including
the choice of allogeneic or autologous HSCT [13-23]. Euro-
pean guidelines for HSCT in autoimmune diseases were
published recently [13]; however, in light of the limited re-
ported evidence, recommendations for immune cytopenias
are based largely on consensus expert opinion, including
a differential approach for children and adults. To provide
further evidence, we analyzed the outcomes of childrenwith
autoimmune cytopenia treated with HSCT in Europe.
METHODS
Twenty-two pediatric patients (age 0-18 years) with refractory auto-
immune cytopenia who underwent autologous or allogeneic HSCT and re-
ported to the European Group for Blood and Marrow Transplantation
(EBMT) registry between January 1997 and February 2009 were included in
this study, which was performed under EBMT governance. Demographic
data and details of pretreatment and HSCTs are presented in Table 1.
The median duration of immune cytopenia was 4.2 years (range,
0.8-6.84 years). All patients with available data on previous treatment had
received numerous lines of immunosuppressive treatment, including
steroids, ciclosporine, rituximab, and cyclophosphamide, and one-half had
undergone splenectomy. Twenty-two patients underwent a total of 24
HSCTs, including 17 allogeneic HSCTs (9 for ES, 5 for AIHA, and 3 for auto-
immune lymphoproliferative syndrome) and 7 autologous HSCTs (2 for ES, 1
for AIHA, and 4 for ITP). Two patients failed to respond or relapsed after
autologous HSCT and subsequently underwent allogeneic HSCT.
The stem cell source for all 7 patients undergoing autologous HSCT
was cyclophosphamide/granulocyte colony-stimulating factoremobilized
peripheral blood stem cells. In the allogeneic HSCT group, the stem cell
source was bone marrow in 10 of 17 cases, granulocyte colony-stimulating
factoremobilized peripheral blood stem cells in 4 cases, and cord blood in
3 cases. Donors for allogeneic HSCT recipients were HLA-identical siblings in
7 cases, unrelated donors in 8 cases, and mismatched relatives in 2 cases.
Grafts were T cell depleted in 5 of 7 autologous HSCTs and in 1 of 17 allo-
geneic HSCTs.
Peripheral blood count measurements were obtained at 1, 3, 6, and 12
months post-HSCT, then yearly, and at the last-follow-up. Responses were
deﬁned as an improvement to levels exceeding 8 g/dL for hemoglobin,
50  109/L for platelets, and 0.5  109/L for neutrophils. Complete remission
(CR) was deﬁned as normalization of blood counts (hemoglobin, >12 g/dL;
neutrophils, >1.5  109/L; platelets, >150  109/L). Event-free survival (EFS)
was deﬁned as the Kaplan-Meier estimate of survival until relapse,
progression of disease, or death, and censored at date of last follow-up.
Outcomes were analyzed for overall survival (OS), EFS, and treatment-
related mortality (TRM), which was deﬁned as the probability of dying
without previous occurrence of relapse. Because of the difﬁculty inTable 1
Patient and Disease Characteristics and HSCT Conditioning Regimens
Autolog
Sex, M/F, n 4/3
Age at diagnosis, years, median (range) 5.13 (0
Age at HSCT, years, median (range) 6.99 (1
Disease duration, years, median (range) 4.2 (1
Follow-up, months, median (range) 126 (1
Previous treatment, n* 4
Splenectomy, n (%) 2 (5
Steroids, n (%) 4 (1
Intravenous immunoglobulins, n (%) 4 (1
Cyclophosphamide, n (%) d
Cyclosporine, n (%) 3 (7
Mycophenolate mofetil, n (%) 2 (5
Rituximab, n (%) 1 (2
Erythropoietin/HSCT, n (%) d
Conditioning, n
Busulfan-based 0
Cyclophosphamide-based  ATG 4
Cyclophosphamide þ ﬂudarabine  ATG 1
Fludarabine  ATG  other 1
Melphalan 1
Data not available d
ATG indicates antithymocyte globulin.
* Data available for19 patients.determining whether death due to hemorragic complications in patients
with ITP should be attributed to the underlying disease or to the treatment,
these deaths were counted as TRM. Failure to respond and relapse of
autoimmune cytopenia were also recorded. Disease recurrence was deﬁned
a relapse after achievement of CR or partial hematologic remission.
Descriptive statistical methods were used with the Kaplan-Meier estimator.
The Fisher exact test was used to assess the differences in OS, EFS, relapse
rate, and TRM. Patients who underwent a second HSCT were censored at the
time of the second procedure, but were included again in the analysis for the
second HSCT.RESULTS AND DISCUSSION
With a median follow-up of 100 months, overall EFS was
54%, with a median survival time of 86 months (95% CI, 55-
116 months). EFS was 58% and median survival time was 93ous HSCT (n ¼ 7) Allogeneic HSCT (n ¼ 17)
10/7
.98-16.33) 4.28 (0.59-17.29)
.73-17.34) 8.24 (0.61-17.77)
.73-5.6) 4.27 (0.8-6.84)
13-132) 76 (6-156)
15
0) 7 (46)
00) 10 (66)
00) 7 (46)
3 (20)
5) 5 (30)
0) 7 (46)
4) 6 (40)
3 (20)
6
3
2
4
0
2
Table 2
Toxicity
Characteristic Autologous
HSCT
Allogeneic
HSCT
Neutrophil recovery (>0.5  109),
days, median (range)
21.5 (7-49) 38.6 (10-110)
(n/n evaluable) 6/7 16/17
Median platelet recovery, days
(PLT > 50) (range)
31 36.9 (11-61)
(n/n evaluable) 1/7 7/17
TRM, n
Infection 1 3
Hemorrhage 0 2
aGVHD, n
Absent 8
Grade I-II 7
Grade III-IV 2
Late events
Chronic GVHD, n/n evaluable 2/11
Death due to disease progression, n 2
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group, compared with 42% and 58 months (95% CI, 10-105
months) in the autologous HSCTgroup (Figure 1). There were
no signiﬁcant differences in outcomes between the 2 groups
(P ¼ .50); however, failure of response or relapse was more
common after autologous HSCT, but the difference was not
statistically signiﬁcant (43% versus 13%; P ¼ .30). Despite
this, deaths due to progression of underlying autoimmune
cytopenia (AIHA and ES) followed allogeneic HSCT.
The median times to platelet recovery (>20  109/L) and
neutrophil recovery (>0.5  109/L) were 37 days (range,
11-61 days) and 39 days (range, 10-110 days), respectively, in
the allogeneic HSCT group and 31 days (range, 10-50 days)
and 22 days (range, 7-49 days) in the autologous HSCTgroup.
TRM occurred in 5 of 15 (29%) allogeneic HSCT recipients and
in 1 of 7 (16%) autologous HSCT recipients (P ¼ .09), mainly
related to infection (4 cases) but also hemorrhage, with 1
case in a patient with ES with persistent disease after allo-
geneic HSCT and the other case in a patient with AIHA during
the aplasia phase. Nine of 17 allogeneic HSCT recipients
developed acute graft-versus-host disease (GVHD; 7 withTable 3
Outcome by Disease
Disease Outcome Autologous
HSCT
Allogeneic
HSCT
Evans
syndrome
n ¼ 2 n ¼ 9
CR 0 5
Death, TRM 0 3
Death, progressive
disease
0 0
No response 1
Relapse 1 1
AIHA n ¼ 1 n ¼ 5
CR 0 2
Disease progression 1 0
Death, TRM 0 2
No response 1
Relapse 0 0
ITP n ¼ 4 n ¼ 0
CR 3 0
Death, TRM 1 0
ALPS n ¼ 0 n ¼ 3
CR 0 3
Death, TRM 0 0
ALPS indicates autoimmune lymphoproliferative syndrome.grade I-II and 2 with III-IV), whereas 2 of 11 evaluable
patients (18%) developed limited chronic GVHD. Treatment-
related toxicities are summarized in Table 2.
EFS is shown in Figure 1. CR was achieved in 10 of 17
allogeneic HSCT recipients and in 3 of 7 autologous HSCT
recipients (all 3 with ITP). All patients in CR were free of
drugs. In contrast to ES, in AIHA, there either was no
response or relapse occurred after a response that fell short
of CR. Outcomes by disease are listed in Table 3.
Although our data are heterogeneous, this small retro-
spective analysis demonstrates long-term responses in
approximately one-half of pediatric patients with severe
refractory autoimmune cytopenia after either allogeneic or
autologous HSCT. Similar to other published reports in
autoimmune disease [24], the high TRM in our cohort may be
explained by the long disease duration and heavy pretreat-
ment with immunosuppressive agents, with HSCT per-
formed essentially as end-stage salvage therapy.
Thus, both autologous and allogeneic HSCTappear to offer
the prospect of long-term disease-free survival in this
generally poor-risk group of patients with nonmalignant
hematologic diseases, in which disease-related mortality is
as high as 30% [10]. Based on the data in this small study, it is
not possible to recommend a deﬁnitive preference for
autologous or allogeneic HSCT in immune cytopenias. In line
with current EBMT guidelines and recommendations, there
is a need for multidisciplinary consideration of individual
cases and further studies. More deﬁnitive data are required
from prospective studies in speciﬁc types of autoimmune
cytopenias in this age group, although the relatively low
number of HSCTs performed in most transplantation centers
poses a major challenge to performing a prospective
randomized study. Standardizing patient selection and
transplantation schedules through noninterventional inter-
national protocols and registration studies, including more
robust deﬁnitions of response criteria and collection of
detailed laboratory parameters, also may produce more
interpretable data on which to base future guidelines and
recommendations.ACKNOWLEDGMENTS
We thank Larissa Cox for secretarial help.
Financial disclosure: There are no conﬂicts of interest to
report.
Authorship statement: Marco Rabusin collected data and
wrote the manuscript. John Snowden reviewed and edited
the manuscript and contributed data. Manuela Badoglio
managed the database and collected data. Dominique Farge
reviewed and edited the manuscript. Riccardo Saccardi and
Giorgio Dini designed research and reviewed themanuscript.
Luca Ronfani, performed the statistical analysis. Paul Veys,
Pierre Quartier, Jean Dalle, Catharina Dooge, Paolo Di
Bartolomeo, Maria Gonzalez-Vicent, Brenda Gibson, Arturo
Iriondo, Herbert Juergens, Igor Lisukov, Chiara Messina,
Valerie Mialou, Colin Steward, Christian Urban, Nagua
Giurici, and Christina Peters provided clinical data and
reviewed the manuscript.REFERENCES
1. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol.
2006;132:125-137.
2. Wang W. Evans syndrome in childhood: pathophysiology, clinical
course, and treatment. Am J Pediatr Hematol Oncol. 1988;15:381-390.
3. Savasan S, Warrier I, Ravindranatah Y. The spectrum of Evans
syndrome. Arch Dis Child. 1997;77:245-248.
M. Rabusin et al. / Biol Blood Marrow Transplant 19 (2013) 661e675 6694. Blouin P, Auvrignon A, Pagnier A, et al. Evans syndrome: a retrospective
study from the ship. Arch Pediatr. 2005;12:1600-1607.
5. Mathew P, Chen G, Wang W. Evans syndrome: results of a national
survey. J Pediatr Hematol Oncol. 1997;19:433-437.
6. Ware RE, Rose WF. Autoimmune hemolytic anemia. In: Nathan DG,
Orkin SH, editors. Nathan and Oski’s hematology of infancy and child-
hood. Philadelphia: Saunders; 1998. p. 499-522.
7. Alajdidi N, Leverger G, Leblanc T, et al. New insight into childhood
hemolytic anemia: a French national observational study of 265 chil-
dren. Hematologica. 2011;96:655-663.
8. Provan D, Stasi R, Newland AC, et al. International consensus report on
the investigation and management of primary immune thrombocyto-
penia. Blood. 2010;115:168-186.
9. Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, et al. Long-term
outcome of chronic idiopathic thrombocytopenic purpura in children.
J Pediatr Hematol Oncol. 2004;26:724-726.
10. Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural
history study at the children’s hospital of Alabama. Clin Pediatr (Phila).
2004;43:691-702.
11. Blanchette VS, Price V. Childhood chronic immune thrombocytopenia
purpura: unresolved issues. J Pediatr Hematol Oncol. 2003;25:S28-S33.
12. Bansal D, Bhamare TA, Trehan A, et al. Outcome of Idiopathic throm-
bocytopenic purpura in children. Pediatr Blood Cancer. 2010;54:
403-407.
13. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic stem cell
transplantation in severe autoimmune diseases: updated guidelines of
the European Group for Blood and Marrow Transplantation. Bone
Marrow Transplant. 2012;47:770-790.
14. Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials
of autologous hematopoietic stem cell transplantation for auto-
immune diseases: the evolution from myeloablative to lym-
phoablative transplant regimens. Arthritis Rheum. 2006;54:
3750-3760.15. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide
with autologous lymphocyte-depleted peripheral blood stem cell
(PBSC) support for treatment of refractory chronic autoimmune
thrombocytopenia. Blood. 2003;101:71-77.
16. Passweg J, Rabusin M, Musso M, et al. Haematopoietic stem cell
transplantation for refractory autoimmune cytopenia. Br J Hematol.
2004;125:749-755.
17. Seeliger S, BaumannM,MohrM, et al. Autologous peripheral blood stem
cell transplantation and anti-B celledirected therapy for refractory
autoimmune hemolytic anemia. Eur J Pediatr. 2001;160:493-496.
18. Raetz E, Beatty PG, Adams RH. Treatment of severe Evans syndrome
with an allogeneic cord blood transplant. Bone Marrow Transplant.
1997;20:427-429.
19. Urban C, Lackner H, Sovinz P, et al. Successful unrelated cord blood
transplantation in a 7-year-old boy with Evans syndrome refractory to
immunosuppression and double autologous stem cell transplantation.
Eur J Hematol. 2006;76:526-530.
20. Marmont A, Gualandi F, Occhini D, et al. Catastrophic relapse of Evans
syndrome ﬁve years after allogeneic BMT notwithstanding full donor
chimerism. Autoimmunity. 2006;39:505-511.
21. Marmont AM. Immune ablation and stem cell transplantation for
severe Evans syndrome and refractory thrombocytopenic purpura.
Bone Marrow Transplant. 1999;23:1215-1216.
22. Pession A, Zama D, Masetti R, et al. Hematopoietic stem cell trans-
plantation for curing children with severe autoimmune diseases: is this
a valid option? Pediatr Transplant. 2012;16:413-425.
23. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem
cell transplantation for autoimmune diseases: an observational study
on 12 years’ experience from the European Group for Blood and
Marrow Transplantation Working Party on Autoimmune Diseases.
Haematologica. 2010;95:284-292.
24. DaikelerT,HugleT,FargeD,etal.AllogeneichematopoieticSCT forpatients
with autoimmune diseases. Bone Marrow Transplant. 2009;44:27-33.
